Flex Pharma Inc  

(Public, NASDAQ:FLKS)   Watch this stock  
Find more results for ELIZABETH HAHN´┐Ż
12.41
+0.25 (2.06%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.70 - 12.51
52 week 11.70 - 24.82
Open 12.06
Vol / Avg. 50,258.00/57,589.00
Mkt cap 218.13M
P/E     -
Div/yield     -
EPS -1.36
Shares 17.94M
Beta     -
Inst. own 54%
Sep 8, 2015
Flex Pharma Inc at Rodman & Renshaw Global Investment Conference Add to calendar
Aug 5, 2015
Q2 2015 Flex Pharma Inc Earnings Release
Aug 5, 2015
Q2 2015 Flex Pharma Inc Earnings Call - Webcast
Jul 8, 2015
Flex Pharma Inc at Cantor Fitzgerald Inaugural Healthcare Conference - Webcast
Jun 24, 2015
Flex Pharma Inc at JMP Securities Life Sciences Conference - Webcast
Jun 23, 2015
Flex Pharma Inc at Jefferies Consumer Conference - Webcast
Jun 9, 2015
Flex Pharma Inc at Piper Jaffray 35th Annual Consumer Conference - Webcast
Jun 4, 2015
Flex Pharma Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -25.91% -
Return on average equity -26.44% -
Employees 19 -
CDP Score - -

Address

800 Boylston St Fl 24
BOSTON, MA 02199-8119
United States - Map
+1-617-8741821 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Flex Pharma, Inc. is a biotechnology company that is developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms for neuromuscular conditions. The Company focuses its drug development efforts on developing a product to treat nocturnal leg cramps. The Company's treatment, which forms the basis of both drug product and consumer product development efforts, activates the transient receptor potential (TRP) cation channel receptors in primary sensory neurons in the spinal cord that enhances overall inhibitory tone in motor neurons throughout the body. The Company's pre-clinical drug product candidates are offered for Nocturnal leg cramps, and MS spasticity, cervical dystonia and/or SCI spasticity. The Company's consumer brand and products focuses athletes experiencing exercise-associated muscle cramps, or EAMCs. The Company has commenced formulation and commercialization efforts of its consumer brand.

Officers and directors

Christoph H. Westphal Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
Marina Hahn President, Consumer
Age: 57
Bio & Compensation  - Reuters
John McCabe Vice President - Finance, Treasurer
Age: 45
Bio & Compensation  - Reuters
Jennifer Cermak Ph.D. Vice President - Research & Development
Age: 42
Bio & Compensation  - Reuters
Robert Hadfield Ph.D. General Counsel, Secretary
Age: 37
Bio & Compensation  - Reuters
Elizabeth Woo M.D., Ph.D. Senior Vice President, Investor Relations and Corporate Communications
Age: 48
Bio & Compensation  - Reuters
Thomas C. Wessel M.D., Ph.D. Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Jeffrey D. Capello Director
Age: 50
Bio & Compensation  - Reuters
Roderick Mackinnon M.D Director
Age: 59
Bio & Compensation  - Reuters
Peter Barton Hutt Non-Executive Independent Director
Age: 80
Bio & Compensation  - Reuters